Loading…
Innate Pharma S.A. is projected to rise to $1.86 by 2027, a +6% move from its current price of $1.75. IPHA is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/3/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 4 | $1.70 | $1.75 | $1.80 | +0.01% |
| Aug 5 | $1.68 | $1.75 | $1.82 | +0.01% |
| Aug 6 | $1.67 | $1.75 | $1.84 | +0.02% |
| Aug 7 | $1.66 | $1.75 | $1.85 | +0.03% |
| Aug 8 | $1.64 | $1.75 | $1.86 | +0.04% |
| Aug 9 | $1.64 | $1.75 | $1.87 | +0.04% |
| Aug 10 | $1.63 | $1.75 | $1.88 | +0.05% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.63 | $1.75 | $1.88 | +0.05% |
| Week 2 | $1.58 | $1.75 | $1.94 | +0.10% |
| Week 3 | $1.54 | $1.75 | $1.99 | +0.15% |
| Week 4 | $1.51 | $1.75 | $2.03 | +0.20% |
| Week 5 | $1.49 | $1.75 | $2.07 | +0.25% |
| Week 6 | $1.47 | $1.76 | $2.10 | +0.30% |
| Week 7 | $1.44 | $1.76 | $2.13 | +0.35% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally.
Incorporated in 1999 and based in Marseille, France, the company has a diverse portfolio spanning multiple investigational programs and antibody–drug conjugates.
Its product portfolio includes Lacutamab (IPH4102), IPH4502, Monalizumab, IPH5201, IPH5301, IPH6401, IPH6101, IPH62 and IPH6501. Innate Pharma has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech.
Innate Pharma S.A. (IPHA) is trading at $1.76 with a market cap of $165.27M, ranking 3854. The symbol for the asset is IPHA.
The forecast indicates a long-term path of rising averages and expanding price ranges, with 2026 avg $1.76 and 2050 avg $8.36, and a 2050 max of $14.59. By year, the model projects higher medians and substantial upside through 2050, with ROI reaching up to 375.2% in 2050 and bullish sentiment prevailing in the later years.
A major floor 28.6% below — a decisive break under it would weaken the trend.
The nearest floor, 4.0% below — buyers have tended to step in here.
The nearest ceiling, 8.6% above — a clean break opens room to run.
A major ceiling 28.6% above — clearing it would confirm fresh momentum.
Key IPHA support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of IPHA market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.75 | Sell | $1.76 | Sell |
| MA 10 | $1.76 | Sell | $1.76 | Sell |
| MA 20 | $1.78 | Sell | $1.77 | Sell |
| MA 50 | $1.80 | Sell | $1.76 | Sell |
| MA 100 | $1.64 | Buy | $1.73 | Buy |
| MA 200 | $1.73 | Buy | $1.76 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 47.63 | Neutral |
| Stoch RSI (14) | 58.65 | Neutral |
| CCI (20) | -66.32 | Neutral |
| Williams %R (14) | -50.00 | Info |
| MACD (12,26,9) | -0.00 | Sell |
| ROC (12) | -2.78 | Sell |
| Bollinger %B (20,2) | 0.32 | Neutral |
| Stochastic %K (14) | 50.00 | Neutral |
| TRIX (15) | -0.07 | Sell |
| Awesome (5,34) | -0.04 | Sell |
| Ultimate (7,14,28) | 46.36 | Neutral |
| Momentum (10) | 0.00 | Neutral |
| Aroon Osc (25) | -60.00 | Sell |
| Hull MA (9) | 1.76 | Sell |
| ADX (14) | 6.79 | Neutral |
| ATR (14) | 0.04 | Info |
Market sentiment is NEUTRAL and the RSI14 is 50.
The 50-day simple moving average stands at $1.81 and the 200-day simple moving average at $1.74. The near-term price action shows a 30-day range of $1.51 to $2.05, with a nearby support at $1.73 and a resistance at $1.90.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.17 | $1.75 | $2.15 | 0% | Neutral | |
| $1.48 | $1.86 | $2.47 | +6% | Neutral | |
| $1.52 | $1.97 | $2.72 | +13% | Neutral | |
| $1.88 | $2.49 | $3.54 | +42% | Bullish | |
| $2.01 | $2.72 | $3.97 | +56% | Bullish | |
| $1.88 | $2.59 | $3.86 | +48% | Bullish | |
| $2.05 | $2.88 | $4.38 | +65% | Bullish | |
| $2.03 | $2.90 | $4.48 | +66% | Bullish | |
| $1.96 | $2.85 | $4.48 | +63% | Bullish | |
| $2.45 | $3.60 | $5.75 | +106% | Bullish | |
| $2.79 | $4.41 | $7.49 | +152% | Bullish | |
| $5.12 | $9.10 | $16.94 | +420% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $1.17 | $1.75 | $2.13 | +0.00% |
| September 2026 | $1.54 | $1.82 | $2.21 | +3.80% |
| October 2026 | $1.48 | $1.76 | $2.17 | -3.03% |
| November 2026 | $1.42 | $1.70 | $2.11 | -3.34% |
| December 2026 | $1.43 | $1.72 | $2.15 | +1.06% |
Click any year to see its month-by-month IPHA forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The IPHA price prediction for 2026 points to an average of $1.75 (low $1.17, high $2.15) — a potential gain of 0% on today's $1.75. A consolidation phase looks the most probable path here.
In 2027, IPHA is projected to trade between $1.48 and $2.47, averaging $1.86 — a potential gain of +6% from today's $1.75. That is up +6% on the projected 2026 average. Price action looks broadly range-bound.
Innate Pharma S.A.'s 2028 outlook centres on $1.97, within a $1.52 to $2.72 range. That is up +6% on the projected 2027 average. That marks a +13% change versus current levels. A consolidation phase looks the most probable path here.
By 2029, IPHA could reach as high as $3.54, with a base case around $2.49 and support toward $1.88 — roughly +42% from $1.75. Momentum favours further upside here.
Expect IPHA to range from $2.01 to $3.97 through 2030. The $2.72 average target implies a +56% move from current prices. That is up +9% on the projected 2029 average. Buyers look set to stay in control over this stretch.
The IPHA price prediction for 2031 points to an average of $2.59 (low $1.88, high $3.86) — a potential gain of +48% on today's $1.75. Momentum favours further upside here.
In 2032, IPHA is projected to trade between $2.05 and $4.38, averaging $2.88 — a potential gain of +65% from today's $1.75. That is up +11% on the projected 2031 average. Buyers look set to stay in control over this stretch.
Innate Pharma S.A.'s 2033 outlook centres on $2.90, within a $2.03 to $4.48 range. That is up +1% on the projected 2032 average. That marks a +66% change versus current levels. Momentum favours further upside here.
By 2034, IPHA could reach as high as $4.48, with a base case around $2.85 and support toward $1.96 — roughly +63% from $1.75. Buyers look set to stay in control over this stretch.
Expect IPHA to range from $2.45 to $5.75 through 2035. The $3.60 average target implies a +106% move from current prices. That is up +26% on the projected 2034 average. Momentum favours further upside here.
The IPHA price prediction for 2040 points to an average of $4.41 (low $2.79, high $7.49) — a potential gain of +152% on today's $1.75. Buyers look set to stay in control over this stretch.
In 2050, IPHA is projected to trade between $5.12 and $16.94, averaging $9.10 — a potential gain of +420% from today's $1.75. That is up +106% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in IPHA today (≈ 571.428571 IPHA) could be worth
$5,197.58
+$4,197.58 (+420%) by 2050 · US Dollar
Based on the average projected IPHA price of $9.1 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in IPHAwould be worth at today's price.
$1,000 invested in IPHA on Jul 31, 2025 (≈ 473.933673 IPHA) would be worth
$829.38
-$170.62 (-17.1%) today · 0.83× · US Dollar
Based on a IPHA entry price of $2.11 vs. today's $1.75.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.78 | $983.15 | -1.7% |
| 1 month ago | $1.81 | $966.85 | -3.3% |
| 3 months ago | $1.44 | $1,215.28 | +21.5% |
| 6 months ago | $1.82 | $961.54 | -3.8% |
| 1 year ago | $2.11 | $829.38 | -17.1% |
| All time (5.0y) ago | $3.3 | $530.3 | -47.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our IPHA forecast.
Our base-case forecast reaches $3.50 around 2035.
Implied market cap at $3.50: $328.66M
The multi-year forecast shows IPHA’s average price rising from $1.76 in 2026 to $2.57 in 2030 and then higher in subsequent years, with 2030, 2031 and 2032 aligned in a bullish phase as the averages expand toward $2.78 and $4.05 respectively. By 2035 the average price is forecast at $3.40 and the max at $5.18, with a 93.3% ROI.
In 2040, the average price is projected to $4.19 and the max to $6.75, with a 138.3% ROI, keeping a BULLISH sentiment. In 2050 the average price is forecast at $8.36 and the max at $14.59, with a 375.2% ROI, signaling a sustained bullish trajectory.
Tap a question to reveal the answer.
The forecast for 2030 shows an average price of $2.57 with a min of $1.96 and a max of $3.63, and a ROI of 46.3%. The sentiment is BULLISH.
Forecasts show a transition to bullish sentiment from 2029 onward, with 2029 avg $2.40 and 2030 avg $2.57 and a 46.3% ROI. These are estimates and not guarantees.
Yes. The 2035 max is $5.18 and the 2040 max is $6.75, indicating the potential to exceed $5 in the forecast horizon.
Neutral sentiment with RSI(14) at 50. The 50-day SMA is $1.81, the 200-day SMA is $1.74. The 30-day range is $1.51–$2.05, with support at $1.73 and resistance at $1.90.
Current price is $1.76 and market cap is $165.27M.
Innate Pharma S.A. Community Discussion
0Share your Innate Pharma S.A. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.